Predictive modelling of tumor response and progression in cervical and head and neck cancers: a retrospective and prospective validation study

A. V. S. Suresh; Mallik Singaraju; Anuradha Vutukuru

doi:10.18203/2394-6040.ijcmph20252162

Authors

A. V. S. Suresh Department of Medical Oncology, Continental Hospitals, Hyderabad, TG, India
Mallik Singaraju Department of Radiation Oncology, Continental Hospitals, Hyderabad, TG, India
Anuradha Vutukuru Department of Pathology, Bhaskar Medical College, Hyderabad, TG, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20252162

Keywords:

Cervical cancer, Head and neck cancer, Predictive modeling, Tumor shrinkage, Fat score, Necrosis, Immune infiltration, Precision oncology

Abstract

Background: Precision oncology aims to tailor treatment based on individual tumor biology and patient-specific factors. Predictive modeling using imaging-derived parameters such as fat score, blood vessel density, necrosis, and immune cell infiltration may enhance early assessment of therapeutic response. This study aims to assess the predictive validity of a novel scoring system for tumor shrinkage, progression-free survival (PFS), and time to maximum response using retrospective data from 500 patients and validate these findings prospectively in 200 patients with cervical and head and neck cancers.

Methods: A retrospective cohort of 500 subjects (50% cervical cancer, 50% head and neck cancer) with varied staging was analyzed to correlate imaging and pathological scores with actual treatment outcomes. A predictive model was applied and validated prospectively on an independent cohort of 200 patients. Parameters included fat content, blood vessel density, necrosis, and immune cell density scores, culminating in an overall score. Model-predicted vs actual outcomes were compared using 90% concordance threshold.

Results: Retrospective data revealed strong correlation between high overall scores and favorable treatment response, including earlier time to maximum shrinkage (mean: 12.1 weeks), higher tumor regression (>50%), and longer PFS (mean: 18.3 months). The prospective cohort confirmed these findings with a 91% model concordance for time to response and 89% for PFS prediction. Multivariate regression highlighted blood vessel density and immune infiltration as the strongest predictors.

Conclusions: The proposed composite scoring system shows promise in predicting therapeutic outcomes and could guide early adaptive therapeutic strategies. Further multi-center validation is warranted.

Metrics

Metrics Loading ...

References

Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. DOI: https://doi.org/10.3322/caac.21820

Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62. DOI: https://doi.org/10.1126/science.1104819

Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. DOI: https://doi.org/10.1038/nrc3245

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646674. DOI: https://doi.org/10.1016/j.cell.2011.02.013

Hajim WI, Zainudin S, Daud KM, Alheeti K. Optimized models and deep learning methods for drug response prediction in cancer treatments: a review. Peer J Computer Sci. 2024;10:1903. DOI: https://doi.org/10.7717/peerj-cs.1903

Eisenhauer EA, Therasse P, Bogaerts J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. DOI: https://doi.org/10.1016/j.ejca.2008.10.026

Jia Q, Wu W, Wang Y. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018;9(1):5361. DOI: https://doi.org/10.1038/s41467-018-07767-w

O'Connor JP, Aboagye EO, Adams JE. Imaging biomarker roadmap for cancer studies. Nat Rev Clin Oncol. 2017;14(3):169–86. DOI: https://doi.org/10.1038/nrclinonc.2016.162

Binnewies M, Roberts EW, Kersten K. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50. DOI: https://doi.org/10.1038/s41591-018-0014-x

Sun R, Limkin EJ, Vakalopoulou M. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti–PD-1 or anti–PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180–91. DOI: https://doi.org/10.1016/S1470-2045(18)30413-3

Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Philadelphia, PA: Elsevier. 2020.

Pérez-García VM, Calvo GF, Bosque JJ. Universal scaling laws rule explosive growth in human cancers. Nat Phys. 2020;16(10):1232–7. DOI: https://doi.org/10.1038/s41567-020-0978-6

Huang C, Huang Y, Xu D. Immune cell infiltration and angiogenesis in cervical cancer: prognostic implications and therapeutic potential. Front Oncol. 2023;13:1172302.